ClinicalTrials.Veeva

Menu

The Effect of Intravenous Infusion of Tramadol-ondansetron on Recovery After Caesarean Section. (TRON)

L

La Fe University and Polytechnic Hospital

Status

Completed

Conditions

ObsQor-10
Quality of Recovery
Postoperative Recovery
Cesarean Section
QoR-15
Tramadol
Postcesarean Recovery
Ondansetron
Post Operative Pain

Treatments

Drug: Ropivacaine via epidural catheter
Drug: Tramadol-ondansetron continuous infusion

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

It will be a prospective observational cohort study. The investigators will compare post-cesarean section recovery in patients receiving intravenous infusion of tramadol-ondansetron versus epidural catheter with infusion of local anesthetics.

Full description

The primary outcome is to assess the non-inferiority in terms of post-cesarean section recovery of the intravenous perfusion of tramadol + ondansetron compared to the perfusion of local anesthetics through an epidural catheter.

This will be a prospective observational cohort study, with a total N of 312 patients who underwent a cesarean section. 156 who maintain the epidural catheter as the main measure of analgesia for 24 h, and 156 who receive an infusion of tramadol-ondansetron from the end of the cesarean section and for the following 24 h. The following data will be collected at 24 and 48 hours: need for unscheduled pharmacological reinforcement, adverse effects, QoR (Quality of Recovery) score 15, ObsQor-10 (Obstetric Quality of Recovery) score, and Visual Analogue Pain Scale (VAS) every 4 hours for 48 hours. The incidence of chronic pain 90 days after cesarean section will be assessed using the Numerical Pain Rating Scale (NRS).

Enrollment

312 patients

Sex

Female

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Woman over 18 years old undergoing caesarean section
  • She agrees to participate voluntarily.
  • She is already receiving any of the analgesic strategies studied.

Exclusion criteria

  • Receiving an analgesic medication other than the one mentioned as "routine multimodal analgesia" (either as regular medication or for acute post-surgical pain)
  • Medical history that determines the baseline data of the scales and data that we collect ( pain or previous disabilities; addiction to drugs, alcohol or drugs; another disease that worsens the quality of life)
  • Medical history that conditions the pharmacological effect (allergy, intolerance or atypical reaction to any of the drugs involved in its treatment or possible cross-reactions )
  • Contraindication for neuraxial techniques (patient refusal, difficulty in understanding or communication, localized infection, increased intracranial pressure, or other medical criteria)
  • Two or more previous caesarean sections
  • Difficulty in understanding or communication
  • Mother care will not be available to the newborn in the postpartum period for any reason

Trial design

312 participants in 2 patient groups

TRON (Tramadol-Ondansetron)
Description:
Women who receive an infusion of tramadol-ondansetron from the end of the cesarean section and for the following 24 h. The infusion (TRON) is composed of 300 mg of tramadol and 12 mg of ondansetron dissolved in 250 ml of 0.9% saline, which is routinely programmed at 11 ml/h until the content is exhausted (approximately 23 hours).
Treatment:
Drug: Tramadol-ondansetron continuous infusion
AL-EPI (Local anesthetics via epidural)
Description:
Women who maintain the epidural catheter as the main measure of analgesia for 24 h. The epidural catheter after caesarean section is programmed with a 0.2% ropivacaine PCA (Patient controlled analgesia) pump at 7 ml/h with 7 ml on-demand boluses, with block every 20 min.
Treatment:
Drug: Ropivacaine via epidural catheter

Trial documents
1

Trial contacts and locations

1

Loading...

Central trial contact

Jose Daniel Jimenez Santana, Resident

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems